-
Press Release
Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile
-
Press Release
Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence
-
Press Release
Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR)
-
Story
Novartis ranks #19 in TIME and Statista’s World’s Best Companies 2026 -
Press Release
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
-
Press Release
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
-
Story
American Chemical Society honors Novartis researchers -
Press Release
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
-
Press Release
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
-
Press Release
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
-
Press Release
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
-
Press Release
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed